stockrow
Saturday 7 November 2026
Export MNKD’s income statement to Excel — free account
MannKind Corporation
MNKD Healthcare Biotechnology
MannKind Corporation’s revenue for fiscal 2025 (year ended December 2025) was $349.0 million, up 22.2% from fiscal 2024.
- Revenue
- +24.0%
- EPS
- −333.3%
- Free cash flow
- −267.7%
- Total debt
- +201.8%
Quarter to September 2026, against a year earlier
3.92
0.16
+4.26%
Follow MNKD
Alert me
| Sep '26 From the 10-Q filed 5 Nov | Jun '26 | Mar '26 | Dec '25 | Older periods | |
|---|---|---|---|---|---|
Piotroski F-Score |
— | 2 | 3 | 4 |
+8 more TTM periods Free account |
| 182.90% | 71.36% | 40.60% | (9.03%) | ||
| (12.29%) | (7.62%) | (4.14%) | 0.99% | ||
ROIC |
0.00% | 2.36% | 4.05% | 10.29% | |
Return on Tangible Assets |
(34.27%) | (23.20%) | (12.01%) | 2.89% | |
Average Days of Receivables |
36.23 | 40.06 | 28.47 | 40.13 | |
Free Cash Flow per Share |
(0.24) | (0.06) | 0.04 | 0.04 | |
Free Cash Flow |
(78.41) | (18.13) | 13.15 | 13.69 | |
Capital Expenditures |
(12.16) | (10.08) | (6.12) | (4.57) | |
| Other line items | |||||
Cash ROIC |
(132.12%) | (3.89%) | 2.65% | 2.37% | |
Accounts Receivable Turnover |
14.15 | 11.19 | 12.65 | 13.91 | |
Accounts Payable Turnover |
0.00 | 9.10 | 8.30 | 11.12 | |
Inventory Turnover |
0.00 | 2.66 | 2.25 | 2.78 | |
Average Days of Payables |
0.00 | 41.60 | 67.02 | 37.49 | |
Days of Inventory on Hand |
0.00 | 167.34 | 204.12 | 146.54 | |
Tax Rate |
(0.06) | (0.10) | (0.16) | 3.17 | |
Research and Development Expense of Revenue |
18.67% | 19.53% | 20.11% | 19.01% | |
Selling, General and Administrative Expense of Revenue |
56.17% | 50.78% | 48.01% | 41.30% | |
Share Based Compensation of Revenue |
0.00% | 7.11% | 7.00% | 6.93% | |
Interest Coverage |
— | 0.19 | 0.37 | 1.02 | |
Operating CF/Net income |
0.89 | 0.18 | (0.81) | 3.11 | |
Depreciation/Fixed assets |
0.00 | 0.26 | 0.22 | 0.16 | |
Capex/Depreciation |
0.00 | (0.45) | (0.34) | (0.35) | |
Revenue per Share |
1.29 | 1.27 | 1.17 | 1.14 | |
Operating CF per Share |
(0.21) | (0.03) | 0.06 | 0.06 | |
Capex per Share |
(0.04) | (0.03) | (0.02) | (0.01) | |
Capex to Sales |
0.03 | 0.03 | 0.02 | 0.01 |
Columns are period end dates · fundamentals updated 5 Nov 2026